ArticleBMC gastroenterology2025
Association between dietary flavonoids intake and metabolic dysfunction-associated steatotic liver disease especially in non-smokers: a cross-sectional study in US adults.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pedalitin as an Interesting Phytocompound with a High Potential for Further Functionalization and Application in the Prevention and Treatment of Lifestyle Diseases-The First Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- Dietary antioxidant capacity, flavonoid subclasses, and metabolic dysfunction-associated fatty liver disease in overweight and obese youth.Journal of health, population, and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between dietary flavonoids and fatty liver disease is still controversial. This study investigated the link between dietary flavonoids intake and metabolic-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD).
methodsThe study utilized data from the National Health and Nutrition Examination Survey cycles of 2007-2010 and 2017-2018. The relationship between dietary flavonoids intake and the prevalence of MAFLD/MASLD was evaluated using multivariate logistic regression models. Subgroup and population attributable fraction were employed to investigate the prevalence of MAFLD/MASLD in different smoking status groups.
resultsThe study included 5,645 participants. The fully adjusted multivariate logistic regression model indicated no significant association between ln flavonoids and MAFLD/MASLD (p > 0.05). Restricted cubic spline analysis identified a nonlinear relationship between ln flavonoids and MAFLD/MASLD, with 4.747 and 4.409 as the turning points, respectively. Subgroup and population attributable fraction analyses revealed that the negative association between flavonoids and MAFLD/MASLD is particularly significant in non-smokers. Mediation analysis indicated that the low-grade inflammation played a crucial role in the association. The study's robustness was validated through sensitivity analyses.
conclusionsOur study highlighted a U-shaped association between ln flavonoids and MAFLD/MASLD, influenced by low-grade inflammation. Encouraging a flavonoid-rich diet is crucial for managing MAFLD/MASLD in non-smokers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.